

**Appendix A.** First-line chemotherapy use over time in patients with Stage IIIB/IV NSCLC 2000 – 2007

~ Due to human subjects' restrictions, the publication of tables with cells containing less than 5 observations is prohibited.

| <b>Year of Diagnosis</b>  | <b>2000</b> | <b>2001</b> | <b>2002</b> | <b>2003</b> | <b>2004</b> | <b>2005</b> | <b>2006</b> | <b>2007</b> | <b>Overall</b> |
|---|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|----------------|
| Number of patients with Stage IIIB/IV NSCLC   | 759         | 805         | 811         | 841         | 867         | 868         | 835         | 828         | 6614           |
| Patients treated with Chemotherapy, N (%)   | 388 (51.1)  | 399 (49.6)  | 402 (49.6)  | 467 (55.5)  | 474 (54.7)  | 507 (58.4)  | 493 (59.0)  | 482 (58.2)  | 3612 (54.6)    |
| % of Patients age $\geq$ 65 treated with Chemotherapy                               | 43.8        | 39.8        | 42.6        | 46.7        | 45.0        | 51.1        | 50.1        | 49.2        | 46.2           |
| <b>Percent of Patients treated with identifiable first-line chemotherapy, N (%)</b> | 362 (47.7)  | 389 (48.3)  | 371 (45.8)  | 450(53.5)   | 445 (51.3)  | 481 (55.4)  | 482 (57.7)  | 478 (57.7)  | 3458 (52.3)    |
| First-line chemotherapy, n (%)  |             |             |             |             |             |             |             |             |                |
| <b>Single-Agent Therapy - Percent (%) of Total</b>                                  | <b>14.7</b> | <b>15.2</b> | <b>11.6</b> | <b>16.7</b> | <b>20.0</b> | <b>21.8</b> | <b>19.8</b> | <b>23.2</b> | <b>18.5</b>    |
| Platinum (cisplatin/carboplatin)  | 6 (1.7)     | 22 (5.7)    | 25 (6.7)    | 30 (6.7)    | 25 (5.6)    | 26 (5.4)    | 22 (4.6)    | 26 (5.4)    | 182 (5.3)      |
| Taxanes   | 10 (2.8)    | 6 (1.5)     | 5 (1.4)     | 8 (1.8)     | < 5         | 9 (1.9)     | 7 (1.5)     | 6 (1.3)     | 55 (1.6)       |
| Erlotinib   | 0           | 0           | 0           | 0           | < 5         | 43 (8.9)    | 49 (10.2)   | 57 (11.9)   | 153 (4.4)      |
| Other Singlet <sup>a</sup>  | 37 (10.2)   | 31 (8.0)    | 13 (3.5)    | 37 (8.2)    | 64 (14.4)   | 27 (5.6)    | 17 (3.5)    | 22 (4.6)    | 248 (7.2)      |

| Year of Diagnosis                             | 2000        | 2001        | 2002        | 2003        | 2004         | 2005         | 2006         | 2007         | Overall     |
|---|-------------|-------------|-------------|-------------|--------------|--------------|--------------|--------------|-------------|
| <b>Doublet Therapy - Percent (%) of Total</b> | <b>82.0</b> | <b>82.5</b> | <b>86.8</b> | <b>81.3</b> | <b>~75.3</b> | <b>~72.4</b> | <b>~73.1</b> | <b>~64.7</b> | <b>77.0</b> |
| Platinums + Taxanes                           | 226 (62.4)  | 241 (62.0)  | 250 (67.4)  | 253 (56.2)  | 262 (58.9)   | 248 (51.6)   | 254 (52.7)   | 196 (41.0)   | 1930 (55.8) |
| Platinums + Gemcitabine                       | 32 (8.8)    | 28 (7.2)    | 33 (8.9)    | 35 (7.8)    | 41 (9.2)     | 43 (8.9)     | 25 (5.2)     | 31 (6.5)     | 268 (7.8)   |
| Platinums + Other                             | 34 (9.4)    | 46 (11.8)   | 27 (7.3)    | 59 (13.1)   | 32 (7.2)     | 57 (11.9)    | 73 (15.2)    | 82 (17.2)    | 410 (11.9)  |
| Other Doublets <sup>b</sup>                   | 5 (1.4)     | 6 (1.5)     | 12 (3.2)    | 19 (4.2)    | < 5          | < 5          | < 5          | < 5          | 52 (1.5)    |
| <b>Triplet Therapy - Percent (%) of Total</b> | <b>3.3</b>  | <b>2.3</b>  | <b>1.6</b>  | <b>~1.1</b> | <b>~1.8</b>  | <b>5.6</b>   | <b>~5.8</b>  | <b>10.9</b>  | <b>4.6</b>  |
| carboplatin + Paclitaxel + Bevacizumab        | 0           | 0           | <5          | 5 (1.1)     | <5           | 17 (3.5)     | 28 (5.8)     | 52 (10.9)    | 103 (3.0)   |
| Others <sup>c</sup>                           | 12(3.3)     | 9 (2.3)     | 6 (1.6)     | <5          | 8 (1.8)      | 10 (2.1)     | <5           | <5           | 57 (1.6)    |

<sup>a</sup> Other single-agent therapies include: amifostine, bevacizumab, bleomycin, capecitabine, cyclophosphamide, danazol, etoposide, fluorouracil, gefitinb, gemcitabine, hydroxyurea, ifosfamide, irinotecan, leucovorin, pemetrexed, plicamycin, temozolomide, thalidomide, vinorelbine

<sup>b</sup> Other doublet therapies include: cyclophosphamide + vincristine, doxorubicin + ifosfamide, gefitinib + vinorelbine, gefitinib + gemcitabine, gemcitabine + vinorelbine, bevacizumab + paclitaxel, docetaxel + gemcitabine, erlotinib + paclitaxel, etoposide + paclitaxel, paclitaxel + vinorelbine

<sup>c</sup> Other triplet therapies include: cisplatin/carboplatin + docetaxel/paclitaxel + (doxorubicin, etoposide, erlotinib, gemcitabine, or vinorelbine), cisplatin + etoposide + (amifostine, fludarabine, mitomycin, or vinorelbine), carboplatin + bevacizumab + (gemcitabine, or erlotinib), cyclophosphamide + doxorubicin + (etoposide, dexrazoxane, or vincristine), fluorouracil + leucovorin + (irinotecan, or oxaliplatin)